GLP-1 safety, transparency, access disruptions
Key Questions
What risks are associated with compounded tirzepatide?
Compounded tirzepatide from Lilly, often sourced from China and mixed with B12, has impurities linked to liver failure and transplants. FDA discourages compounded versions; use only FDA-approved drugs.
Why did FDA warn Novo Nordisk about their GLP-1 drugs?
Novo Nordisk failed to report three deaths and suicidal thoughts associated with their weight-loss drugs. Patients should monitor mental health and report adverse events promptly.
Are there vision risks with GLP-1 medications?
Optometrists warn of rare risks like NAION, retinopathy, AMD, and DME with GLP-1 drugs such as semaglutide. Users should get regular eye exams and be vigilant for vision changes.
What is the 'dose escalation trap' for GLP-1 drugs?
Rapid dose increases can lead to side effects; microdosing or slower escalation may be better. Consult a doctor before changing doses, avoiding standard protocols if needed.
What is Foundayo and its significance?
Foundayo is the first FDA-approved oral GLP-1 weight loss drug, offering a pill alternative to injections. It provides easier access without compounding risks.
What did NICE approve for semaglutide?
NICE approved semaglutide for reducing major cardiovascular events in overweight or obese patients with cardiovascular disease. This expands its use beyond weight loss.
Why avoid compounded GLP-1 drugs?
Compounded versions lack FDA oversight, leading to impurities, inconsistent dosing, and safety issues like liver damage. Stick to approved brands from Lilly or Novo for safety.
What other GLP-1 developments are noted?
Retatrutide trials saw Mayo Clinic dropouts; FDA issued warnings to unapproved weight loss drug marketers. Prioritize FDA-approved options amid access disruptions.
Lilly compounded tirzepatide+B12 impurities cause liver failure/transplant (China sourcing warning); Novo unreported 3 deaths/suicidal; vision NAION/retinopathy/AMD/DME; dose trap/microdosing; Foundayo oral approved; NICE CV; retatrutide/Mayo dropout; discourage compounds/FDA-approved only.